CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
May 2016—Abbott demonstrated a prototype of the company’s next-generation molecular diagnostics platform at a recent scientific event hosted for its customers. The new system is currently being designed from the ground up based on extensive input from laboratory customers.
“Our molecular lab customers tell us they are facing pressures to do more with less,” John Carrino, divisional vice president of research and development, Abbott Molecular Diagnostics, said in a statement. “Abbott’s next-generation molecular system is being designed to have a faster turnaround time, greater flexibility to run any test at any time, an ability to run higher volumes, and automation to increase lab efficiency—all without compromising the testing performance and quality for which our organization is highly regarded.”
Abbott, 800-553-7042